尿路基因制药

最新新闻

• 评级变动
  Ladenburg Thalmann Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $43
  \u5e02\u573a\u8d44\u8baf · 2026/5/11
• 评级变动
  Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/5/19
• A Quick Look at Today's Ratings for UroGen Pharma Ltd(URGN.US), With a Forecast Between $48 to $75
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Urogen Pharma (URGN) Receives a Buy From H.C. Wainwright
  TipRanks · 2026/5/27
• Goldman Sachs Maintains UroGen Pharma Ltd(URGN.US) With Hold Rating, Raises Target Price to $44
  \u5e02\u573a\u8d44\u8baf · 2026/7/16
• 评级变动
  Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $42
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  Piper Sandler Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/4/20
• 评级变动
  H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/4/23
• Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $60
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $50
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  Piper Sandler Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/2/13
• 评级变动
  Ladenburg Thalmann Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $55
  \u5e02\u573a\u8d44\u8baf · 2025/11/8
• 评级变动
  Jefferies Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/4/10
• H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $75
  \u5e02\u573a\u8d44\u8baf · 2026/8/21
• 评级变动
  TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/6/16
• 评级变动
  Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $50
  \u5e02\u573a\u8d44\u8baf · 2026/7/16
• 评级变动
  Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $32
  \u5e02\u573a\u8d44\u8baf · 2026/2/2
• 评级变动
  H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $45
  \u5e02\u573a\u8d44\u8baf · 2026/5/11
• 评级变动
  H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/7/16

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。